Literatur
Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242
Bertsias GK, Nakou M, Choulaki C et al (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 60:207–218
Dolff S, Quandt D, Feldkamp T et al (2014) Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-gamma production and altered IL-17 production in patients with systemic lupus erythematosus. Scand J Rheumatol 43:307–313
Nishimura H, Nose M, Hiai H et al (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151
Wilde B, Hua F, Dolff S et al (2012) Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 51:1188–1197
Metcalfe W, Anderson J, Trinh VA et al (2015) Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discov Med 19:393–401
Demmers MW, Korevaar SS, Roemeling-van Rhijn M et al (2015) Human renal tubular epithelial cells suppress alloreactive T cell proliferation. Clin Exp Immunol 179:509–519
Starke A, Lindenmeyer MT, Segerer S et al (2010) Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int 78:38–47
Reynolds J, Sando GS, Marsh OB et al (2012) Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant 27:1343–1350
Ooi JD, Li M, Kourkoutzelos K et al (2015) Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis. Nephrology (Carlton) 20:892–898
Tanaka K, Albin MJ, Yuan X et al (2007) PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 179:5204–5210
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
B. Wilde hat Reisekostenunterstützung von Alexion, Chiesi, TEVA, Sanofi und Wyeth erhalten. J. Subburayalu gibt an, dass kein Interessenkonflikt besteht.
Additional information
Redaktion
O. Witzke, Essen
Rights and permissions
About this article
Cite this article
Subburayalu, J., Wilde, B. “Programmed-cell-death”-Protein 1 (PD-1/CD279). Nephrologe 11, 70–72 (2016). https://doi.org/10.1007/s11560-015-0037-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-015-0037-y